Getting the Right Evidence After Drug Approval
Publication date
2020-09-09
Authors
Vreman, Rick A.
Leufkens, H.G.
Kesselheim, Aaron S
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
To generate comparative evidence in a timely fashion for drugs without restricting or delaying access, value-based pricing and reimbursement could be conditioned on a prospective, post-approval evidence generation plan.
Keywords
evidence, comparative evidence, regulation, pricing, value-based, health technology assessment, reimbursement
Citation
Vreman, R A, Leufkens, H G M & Kesselheim, A S 2020, 'Getting the Right Evidence After Drug Approval', Frontiers in Pharmacology, vol. 11, 569535. https://doi.org/10.3389/fphar.2020.569535